

GILEAD SCIENCES INC  
Form 8-K  
December 21, 2004

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of report (Date of earliest event reported): **December 20, 2004**

**GILEAD SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**  
(State or other jurisdiction of  
incorporation or organization)

**0-19731**  
(Commission File Number)

**94-3047598**  
(I.R.S. Employer Identification No.)

**333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA**

(Address of principal executive offices)

Edgar Filing: GILEAD SCIENCES INC - Form 8-K

**94404**

(Zip Code)

**(650) 574-3000**

(Registrant's telephone number, including area code)

---

**SECTION 1 REGISTRANT'S BUSINESS AND OPERATIONS**

**Item 1.01 Entry into a Material Definitive Agreement.**

On December 17, 2004, Gilead Sciences, Inc., together with Bristol-Myers Squibb Company, entered into a Collaboration Agreement with a newly-formed, jointly owned limited liability company, Bristol-Myers Squibb & Gilead Sciences, LLC. Pursuant to the terms of the Collaboration Agreement, the companies agreed to work jointly to develop and commercialize the fixed-dose combination of Gilead's Truvada<sup>SM</sup> (emtricitabine and tenofovir disoproxil fumarate) and Bristol-Myers Squibb's Sustiva<sup>®</sup> (efavirenz) in the United States.

A copy of the press release further describing this collaboration is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

**SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS**

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release, dated December 20, 2004, entitled Bristol-Myers Squibb and Gilead Sciences Establish U.S. Joint Venture to Develop and Commercialize Fixed-Dose Combination of Three HIV Medicines.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GILEAD SCIENCES, INC.**

Dated: December 20, 2004

By:

/s/ John F. Milligan  
John F. Milligan  
Executive Vice President and  
Chief Financial Officer